keyword
MENU ▼
Read by QxMD icon Read
search

BPH medication

keyword
https://www.readbyqxmd.com/read/28934186/opioid-overdose-outbreak-west-virginia-august-2016
#1
Joel Massey, Michael Kilkenny, Samantha Batdorf, Sarah K Sanders, Debra Ellison, John Halpin, R Matthew Gladden, Danae Bixler, Loretta Haddy, Rahul Gupta
On August 15, 2016, the Mayor's Office of Drug Control Policy in Huntington, West Virginia, notified the Cabell-Huntington Health Department (CHHD) of multiple calls regarding opioid overdose received by the emergency medical system (EMS) during 3 p.m.-8 p.m. that day. A public health investigation and response conducted by the West Virginia Bureau for Public Health (BPH) and CHHD identified 20 opioid overdose cases within a 53-hour period in Cabell County; all cases included emergency department (ED) encounters...
September 22, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28904902/technique-considerations-and-complication-management-in-transurethral-resection-of-the-prostate-and-photoselective-vaporization-of-the-prostate
#2
REVIEW
Charles Welliver, Sevann Helo, Kevin T McVary
The prevalence of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) increases with age. While a variety of treatments are available for these men, endoscopic treatments are generally preferred for men with small to moderate size glands. Novel treatment options are continually introduced into this large market. However, the practicing urologist should have a well tested surgical option in regular practice that is applicable to a wide range of patients. Herein we discuss two well recognized surgical options that can be used for the majority of men with LUTS due to BPH who have failed medical management...
August 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28860050/a-prospective-study-to-evaluate-sexual-dysfunction-and-enlargement-of-seminal-vesicles-in-sexually-active-men-treated-for-benign-prostatic-hyperplasia-by-alpha-blockers
#3
Ashok Kumar Sokhal, Satyanarayan Sankhwar, Apul Goel, Kawaljit Singh, Manoj Kumar, Bimalesh Purkait, Durgesh Kumar Saini
OBJECTIVE-: To evaluate sexual dysfunction and enlargement of seminal vesicles in sexually active male who were treated by α1-blockers for benign prostatic hyperplasia and its possible clinical application. METHODS-: A prospective cohort study from January 2015 to December 2016. We enrolled sexually active men above the age of 40 years having moderate to severe lower urinary tract symptoms. We excluded patients with a history of prostate surgery, suspicious DRE findings, serum PSA >4 ng/dl, history of medication with anticholinergic/cholinergic /diuretic agents...
August 28, 2017: Urology
https://www.readbyqxmd.com/read/28856711/rationale-and-design-of-the-canari-study-a-case-control-study-investigating-the-association-between-prostate-cancer-and-5-alpha-reductase-inhibitors-for-symptomatic-benign-prostate-hypertrophy-by-linking-sniiram-and-pathology-laboratories-in-a-specific-region
#4
Lucie-Marie Scailteux, Frédéric Balusson, Sébastien Vincendeau, Nathalie Rioux-Leclercq, Emmanuel Nowak
Benign prostate hypertrophy (BPH) could be associated with low urinary symptoms requiring medical treatment: 5 alpha-reductase inhibitors (5-ARI) or ɑ-blockers. Two clinical trials investigating 5-ARI use in prostate cancer (PCa) primary prevention highlighted a potential safety signal with an increased risk of high grade PCa. Later observational studies failed to show similar results but have some limits. The present paper focuses on describing the protocol of the CANARI study and its feasibility, as regards the matching process of two pseudo-anonymous databases...
August 30, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/28840969/intraprostatic-botulinum-toxin-type-a-injection-in-patients-with-benign-prostatic-hyperplasia-and-unsatisfactory-response-to-medical-therapy-a-randomized-double-blind-controlled-trial-using-urodynamic-evaluation
#5
Angelo Totaro, Francesco Pinto, Dario Pugliese, Matteo Vittori, Marco Racioppi, Nazario Foschi, Pier Francesco Bassi, Emilio Sacco
AIMS: The injection of botulinum neurotoxin A (BTA) into the prostate represents a minimally invasive treatment in patients with lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia (BPH). We evaluated the effectiveness of BTA in treating patients with BPH unresponsive to combined medical therapy (CMT), using urodynamic investigations. METHODS: This is a randomized, placebo-controlled, double blind trial. Twenty consecutive patients were randomly assigned to receive intraprostatic BTA injection (n = 10) or saline solution (SS) (n = 10)...
August 25, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28829208/emerging-drugs-for-the-treatment-of-benign-prostatic-hyperplasia
#6
REVIEW
Dominique Thomas, Bilal Chughtai, Mitali Kini, Alexis Te
Benign prostatic hyperplasia (BPH) is a common condition affecting over 50% of men as they reach their 5(th) decade of life. This leads to a number of sequelae such as lower urinary tract symptoms, urinary retention and a decrease in quality of life. Currently, the available treatments for BPH are alpha blockers and 5-alpha reductase inhibitors. Clinical studies have demonstrated these medical options are effective in alleviating a patient's symptoms, however there are a number of side effects. There is a paucity of information regarding long-term use of these medications...
September 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/28800482/targeting-phenotypic-heterogeneity-in-benign-prostatic-hyperplasia
#7
REVIEW
Douglas W Strand, Daniel N Costa, Franto Francis, William A Ricke, Claus G Roehrborn
Benign prostatic hyperplasia and associated lower urinary tract symptoms remain difficult to treat medically, resulting in hundreds of thousands of surgeries performed annually in elderly males. New therapies have not improved clinical outcomes since alpha blockers and 5 alpha reductase inhibitors were introduced in the 1990s. An underappreciated confounder to identifying novel targets is pathological heterogeneity. Individual patients display unique phenotypes, composed of distinct cell types. We have yet to develop a cellular or molecular understanding of these unique phenotypes, which has led to failure in developing targeted therapies for personalized medicine...
August 4, 2017: Differentiation; Research in Biological Diversity
https://www.readbyqxmd.com/read/28796057/risk-factors-for-bladder-calculi-in-patients-with-benign-prostatic-hyperplasia
#8
Wei Huang, Jun-Jie Cao, Min Cao, Hong-Shen Wu, Yong-Yi Yang, Zi-Meng Xu, Xiao-Dong Jin
We aim to find the risk factors that influence the formation of bladder calculi in patients with benign prostate hyperplasia (BPH) and to reduce the surgical intervention related to bladder calculi.Between January 2015 and October 2016, 332 patients with BPH underwent surgical therapy were retrospectively evaluated. Patients with BPH were categorized into 2 groups: 94 patients with bladder calculi in group 1 and 238 patients without bladder calculi in group 2. Medical history, age, body mass index (BMI), total prostate specific antigen, total prostate volume (TPV), International Prostate Symptom Score (IPSS), intravesical prostatic protrusion (IPP), urodynamic parameters, and urine culture were compared between groups...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28795417/molecular-pathogenesis-of-human-prostate-basal-cell-hyperplasia
#9
Gervaise Henry, Alicia Malewska, Ryan Mauck, Jeffrey Gahan, Ryan Hutchinson, Jose Torrealba, Franto Francis, Claus Roehrborn, Douglas Strand
BACKGROUND: Understanding the molecular pathogenesis of distinct phenotypes in human benign prostatic hyperplasia (BPH) is essential to improving therapeutic intervention. Current therapies target smooth muscle and luminal epithelia for relief of lower urinary tract symptoms (LUTS) due to BPH, but basal cell hyperplasia (BCH) remains untargeted. The incidence of has been reported at 8-10%, but a molecular and cellular characterization has not been performed on this phenotype. METHODS: Using freshly digested tissue from surgical specimens, we performed RNA-seq analysis of flow cytometry-purified basal epithelia from 3 patients with and 4 patients without a majority BCH phenotype...
May 2017: Prostate
https://www.readbyqxmd.com/read/28791231/medium-term-efficacy-of-the-prostatic-urethral-lift
#10
REVIEW
Peter Chin, Peter Robertson
Treatment options for patients with benign prostatic hyperplasia have traditionally revolved around pharmacotherapy or invasive surgery, both of which can negatively impact quality of life (QoL). The quest for a suitable minimally invasive surgical therapy as an alternative to long-term medication or conventional surgery, has seen the development of heat-based therapies, most of which have been dismissed because of post-operative complications and unacceptable re-treatment rates. During the late 1980s and 1990s, mechanical approaches such as transurethral balloon dilation and prostatic urethral stenting were investigated; however, re-treatment rates, encrustation and unacceptable migration rate of stents saw these options fall into disuse...
July 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28766115/is-there-a-role-for-preoperative-5-alpha-reductase-inhibitors-in-reducing-prostate-vascularity-and-blood-loss
#11
REVIEW
Matthew Bruha, Charles Welliver
Benign prostatic hyperplasia (BPH) and the related medical problems are a major burden as health care costs and as a cause of patient morbidity. The introduction of medical therapy largely offered an alternative to surgical therapy, and these medications have been linked with multiple positive BPH-related outcomes. With ubiquitous use, however, a variety of adverse side effects and unsupported claims to these medications have been reported both in scientific literature and popular press. The use of 5 alpha reductase inhibitors (5ARIs) to reduce recurrent bleeding due to BPH is a reasonable option for men with recurrent trips to the physician or hospital...
October 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28763255/transurethral-resection-of-the-prostate-achieves-favorable-outcomes-in-stroke-patients-with-symptomatic-benign-prostate-hyperplasia
#12
Chen-Pang Hou, Yu-Hsiang Lin, Tien-Hsing Chen, Phei-Lang Chang, Horng-Heng Juang, Chien-Lun Chen, Pei-Shan Yang, Ke-Hung Tsui
OBJECTIVES: To evaluate the surgical outcomes of stroke patients with symptomatic benign prostatic hyperplasia (BPH) who underwent transurethral resection of the prostate (TURP) and compare the clinical outcomes between patients with stroke and those without stroke receiving this procedure. METHODS: This retrospective cohort study analyzed claims data collected during the period of 1997-2012 from Taiwan National Health Insurance Research Database. We enrolled 6625 patients who had persistent lower urinary tract symptoms and underwent TURP for BPH...
August 1, 2017: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
https://www.readbyqxmd.com/read/28757757/current-consensus-and-controversy-on-the-diagnosis-of-male-lower-urinary-tract-symptoms-benign-prostatic-hyperplasia
#13
REVIEW
Cheng-Ling Lee, Hann-Chorng Kuo
Traditionally, male lower urinary tract symptoms (LUTS) have been considered a synonym for benign prostate hyperplasia (BPH) because most male LUTS develops in aging men. Medical treatment should be the first-line treatment for BPH and surgical intervention should be performed when there are complications or LUTS refractory to medical treatment. Recent investigations have revealed that bladder dysfunction and bladder outlet dysfunction contribute equally to male LUTS. In the diagnosis of LUTS suggestive of BPH (LUTS/BPH), the following questions should be considered: Is there an obstruction? Are the LUTS caused by an enlarged prostate? What are the appropriate tools to diagnose an obstructive BPH? Should patients with LUTS be treated before bladder outlet obstruction is confirmed? This article discusses the current consensus and controversies in the diagnosis of LUTS/BPH...
January 2017: Ci Ji Yi Xue za Zhi, Tzu-chi Medical Journal
https://www.readbyqxmd.com/read/28757756/current-consensus-and-controversy-on-the-treatment-of-male-lower-urinary-tract-symptoms-benign-prostatic-hyperplasia
#14
REVIEW
Chun-Hou Liao, Hann-Chorng Kuo
Lower urinary tract symptoms (LUTS) are highly prevalent in men and increase with age. Because LUTS are common among elderly men, they are usually considered synonymous with benign prostatic hyperplasia (BPH). Drugs should be the first-line treatment for BPH and surgical intervention should be performed only when there are complications or LUTS refractory to medical treatment. In addition to medical treatment, several minimally invasive therapies, such as thermal therapy, prostatic lift, laser evaporation, or laser enucleation techniques have been developed...
January 2017: Ci Ji Yi Xue za Zhi, Tzu-chi Medical Journal
https://www.readbyqxmd.com/read/28730999/surgery-for-benign-prostatic-hyperplasia-profile-of-patients-in-a-tertiary-care-institution
#15
Rahul Rajeev, Bhuwan Giri, Lok Prakash Choudhary, Rajeev Kumar
BACKGROUND: Medical therapy is widely used for managing benign prostatic hyperplasia (BPH) and has made an impact on the profile of patients who ultimately undergo surgery. This changing profile may impact outcomes of surgery and associated complications. To assess the impact of medical management, we evaluated the profile of patients who had surgery for BPH at our institution. METHODS: A retrospective chart-review was performed of patient demographics, indications for surgery, preoperative comorbid conditions and postoperative course in patients who underwent surgery for BPH over a 5-year period...
January 2017: National Medical Journal of India
https://www.readbyqxmd.com/read/28721281/safety-and-efficacy-of-tamsulosin-alfuzosin-or-silodosin-as-monotherapy-for-luts-in-bph-a-double-blind-randomized-trial
#16
Chikka Moga Siddaiah Manohar, Mahadevappa Nagabhushana, Vilvapathy Senguttuvan Karthikeyan, Ramachandra Pudakalkatti Sanjay, Ananth Janardhan Kamath, Ramaiah Keshavamurthy
INTRODUCTION: Currently alpha1-adrenoceptor blockers (AB) are widely used as first-line therapy to improve lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). We compared the efficacy and safety profile of tamsulosin, alfuzosin and silodosin in LUTS due to BPH. MATERIAL AND METHODS: Consecutive consenting male patients (N = 269) undergoing medical management of BPH with AB from February 2012 to October 2015 were enrolled. Patients were randomized to a 0...
June 30, 2017: Central European Journal of Urology
https://www.readbyqxmd.com/read/28665456/is-early-benign-prostatic-hyperplasia-bph-treatment-worthwhile
#17
Fabrizio Presicce, Cosimo De Nunzio, Andrea Tubaro
BACKGROUND: The medical armamentaria for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) have been extensively implemented over the past decade. Nevertheless, the timeliest moment for a possible treatment has not been fully established. EVIDENCE ACQUISITION: A systematic literature search in January 1996 until June 2016 was performed to answer the following question: in men with LUTS due to BPH, does early treatment result in better outcome? An ad hoc Population/patient Intervention/indicator Comparator/control Outcome (PICO) was developed...
June 19, 2017: Urologia
https://www.readbyqxmd.com/read/28646943/state-of-the-art-advanced-techniques-for-prostatic-urethral-lift-for-the-relief-of-prostate-obstruction-under-local-anesthesia
#18
Lance Patrick Walsh
Benign prostatic hypertrophy (BPH) affects an estimated 60% of men over the age of 50 and 90% of men over the age of 80. The prostatic urethral lift (PUL) is a safe and effective office-based procedure that is used worldwide for the treatment of BPH in men who are dissatisfied with medications due to side effects or lack of efficacy or don't want to have a transurethral resection of the prostate due to the side effects and invasiveness of the procedure. In 2012 Barkin et al, published the standard technique for the delivery of the Urolift implant...
June 2017: Canadian Journal of Urology
https://www.readbyqxmd.com/read/28631916/-intravesical-prostatic-protrusion-in-diagnosing-infravesical-obstruction-in-men-with-benign-prostatic-hyperplasia
#19
G G Krivoborodov, N S Efremov, A D Bolotov
Infravesical obstruction (IVO) is an important characteristic of the functional state of male lower urinary tract. It is believed that IVO confirmed by pressure-flow study findings warrants switching from a medical to surgical management of lower urinary tract symptoms (LUTS). Intravesical prostatic protrusion (IPP) is a new indicator for detecting IVO secondary to benign prostatic hyperplasia (BPH). This indicator has several advantages over other non-invasive methods for evaluating IVO. The initial findings on the relationship between IPP and IVO suggest the feasibility of its clinical use as a screening tool in men with obstructive voiding symptoms...
June 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/28631905/-rationale-of-pharmacotherapy-duration-in-patients-with-benign-prostatic-hyperplasia-a-clinical-morphological-study
#20
M E Sitdykova, D E Tsyplakov, E N Sitdykov, A R Nurtdinov
AIM: To investigate the nature of morphological alterations in the urinary bladder wall in BPH patients receiving pharmacotherapy to establish treatment time limits. MATERIALS AND METHODS: The study comprised 120 BPH patients who underwent a transvesical adenomectomy. Prior to the surgery, 110 patients received pharmacotherapy (-blockers and 5-reductase inhibitors) lasting from 1-6 months to 5-10 years. Preoperative evaluation included a standard diagnostic algorithm...
June 2017: Urologii︠a︡
keyword
keyword
79263
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"